|Dr. Vasant Narasimhan||Chief Exec. Officer||5,14M||N/A||1976|
|Mr. Harry Kirsch||Chief Financial Officer||2,61M||N/A||1965|
|Dr. Klaus Moosmayer Ph.D.||Chief Ethics, Risk & Compliance Officer||1,42M||N/A||1968|
|Ms. Karen L. Hale||Chief Legal Officer||2,14M||N/A||1968|
|Dr. Robert Kowalski Pharm.D.||Chief People & Organization Officer||1,92M||N/A||1968|
|Dr. Steffen Lang Ph.D.||Pres of Operations||2,14M||N/A||1967|
|Mr. Victor Bulto||Pres of Innovative Medicines US||2,39M||N/A||N/A|
|Dr. Shreeram Aradhye M.D.||Pres of Global Drug Devel. & Chief Medical Officer||2,09M||N/A||1963|
|Mr. Aharon Gal Ph.D.||Chief Strategy & Growth Officer||5,75M||N/A||N/A|
|Mr. Richard Saynor||Chief Exec. Officer of Sandoz||2,41M||N/A||1967|
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AGs ISS Governance QualityScore, Stand 1. September 2023, lautet 1. Die grundlegenden Scores sind Audit: 1, Vorstand: 2, Shareholderrechte: 1, Kompensation: 1.